
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.
Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).






